Skip to content
Ranexa, Ranexa (previously latixa)(ranolazine)
Aspruzyo, Latixa, Ranexa (ranolazine) is a small molecule pharmaceutical. Ranolazine was first approved as Ranexa on 2006-01-27. It is used to treat angina pectoris in the USA. It has been approved in Europe to treat angina pectoris.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Aspruzyo (generic drugs available since 2013-07-29, discontinued: Ranexa)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ranolazine
Tradename
Company
Number
Date
Products
ASPRUZYO SPRINKLESun PharmaceuticalsN-216018 RX2022-02-28
2 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
aspruzyo sprinkleNew Drug Application2022-03-02
ranexaNew Drug Application2020-12-01
ranolazineANDA2023-05-16
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
angina pectorisEFO_0003913D000787I20
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Ranolazine, Aspruzyo Sprinkle, Spil
108984442038-01-24DP
115108782038-01-24DP
ATC Codes
C: Cardiovascular system drugs
C01: Cardiac therapy drugs
C01E: Other cardiac preparations in atc
C01EB: Other plain cardiac preparations in atc
C01EB18: Ranolazine
HCPCS
No data
Clinical
Clinical Trials
82 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery diseaseD003324I25.1148113
Type 2 diabetes mellitusD003924EFO_0001360E113142111
Myocardial ischemiaD017202EFO_1001375I20-I2532318
Atrial fibrillationD001281EFO_0000275I48.042117
Stable anginaD060050I20.855
Angina pectorisD000787EFO_0003913I20123
Pulmonary hypertensionD006976EFO_0001361I27.2033
Microvascular anginaD017566112
Metabolic syndromeD024821EFO_0000195E88.8122
Ventricular tachycardiaD017180I47.2112
Show 16 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I501113
Pulmonary arterial hypertensionD000081029112
RecurrenceD012008111
Irritable bowel syndromeD043183EFO_0000555K58111
Type 1 diabetes mellitusD003922EFO_0001359E1011
Sudden death cardiacD016757EFO_000427811
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diastolic heart failureD054144EFO_1000899I50.30112
Crohn diseaseD003424EFO_0000384K5011
Inflammatory bowel diseasesD015212EFO_000376711
Dilated cardiomyopathyD002311EFO_0000407I42.011
Acute coronary syndromeD054058EFO_000567211
Romano-ward syndromeD029597Orphanet_101016I45.811
Long qt syndromeD008133HP_0001657I45.8111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD01059911
Myotonic disordersD020967Orphanet_606G71.111
Myotonic dystrophyD009223G71.1111
Myotonia congenitaD009224G71.1211
Renal insufficiencyD051437HP_0000083N1911
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiac arrhythmiasD001145EFO_0004269I49.911
EchocardiographyD00445211
Prostatic neoplasmsD011471C6111
Heart diseasesD006331EFO_0003777I51.911
HemorrhageD006470MP_0001914R5811
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRANOLAZINE
INNranolazine
Description
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide is an aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline. It is a monocarboxylic acid amide, an aromatic amide, a N-alkylpiperazine, a secondary alcohol and a monomethoxybenzene.
Classification
Small molecule
Drug classantiarrhythmic/antianginal/antihypertensive agents, phthalazine like structure
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1
Identifiers
PDB
CAS-ID95635-55-5
RxCUI35829
ChEMBL IDCHEMBL1404
ChEBI ID87690
PubChem CID56959
DrugBankDB00243
UNII IDA6IEZ5M406 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Ranexa - Gilead Sciences
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,472 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
10,012 adverse events reported
View more details